Hellerstein D J, Yanowitch P, Rosenthal J, Samstag L W, Maurer M, Kasch K, Burrows L, Poster M, Cantillon M, Winston A
Psychiatric Outpatient Service, Beth Israel Medical Center, New York, NY 10003.
Am J Psychiatry. 1993 Aug;150(8):1169-75. doi: 10.1176/ajp.150.8.1169.
The purpose of this study was to assess the efficacy of fluoxetine, a selective serotonergic antidepressant, in the treatment of dysthymia.
Thirty-five patients who met criteria for dysthymia, but not major depression, began randomized, double-blind 8-week trials of fluoxetine or placebo.
Of 32 patients who completed the study, 10 (62.5%) of the 16 patients given fluoxetine and three (18.8%) of the 16 given placebo responded to treatment. Response was defined as 1) 50% or greater decrease in Hamilton Rating Scale for Depression score and 2) a score of 1 or 2 on the Clinical Global Impression (CGI) improvement subscale. Fluoxetine subjects showed significantly greater improvement at week 8 than placebo subjects on the Hamilton depression and CGI scales, but not on the Hopkins Symptom Check-list (58-item) or the Cornell Dysthymia Rating Scale.
When compared to placebo, fluoxetine showed short-term effectiveness in treating dysthymic symptoms.
本研究旨在评估选择性5-羟色胺能抗抑郁药氟西汀治疗心境恶劣障碍的疗效。
35例符合心境恶劣障碍而非重度抑郁标准的患者开始了氟西汀或安慰剂的随机、双盲8周试验。
在完成研究的32例患者中，16例服用氟西汀的患者中有10例（62.5%）对治疗有反应，16例服用安慰剂的患者中有3例（18.8%）对治疗有反应。反应定义为：1）汉密尔顿抑郁量表评分降低50%或更多；2）临床总体印象（CGI）改善分量表评分为1或2。在第8周时，氟西汀组患者在汉密尔顿抑郁量表和CGI量表上的改善明显大于安慰剂组，但在霍普金斯症状清单（58项）或康奈尔心境恶劣障碍评定量表上则不然。
与安慰剂相比，氟西汀在治疗心境恶劣障碍症状方面显示出短期疗效。
